Search IconSearch

Driving Out Treatment Resistance: the Center of Excellence in Lymphoid Malignancies Research

Lymphocenter investigates therapeutic resistance and more


Lerner Research Institute recently announced funding for two new Centers of Excellence (COE)—the Center for Research Excellence in Gynecologic Cancer (CREGC) and the Center of Excellence in Lymphoid Malignancies Research (Lymphocenter). With the creation of these two new centers, the COE program — designed to speed the translation of lab discoveries into real benefits for patients — grows larger than ever before, now boasting 12 cross-institute centers.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The Lymphocenter seeks to uncover the mechanisms that drive resistance to treatments for lymphocyte cancers like lymphoma and certain types of leukemia.

The Lymphocenter will support three projects that aim to investigate the molecular mechanisms underlying therapeutic resistance and disease relapse, develop novel cellular immunotherapies and analyze physiological outcomes of novel therapies using patient samples. These projects will also explore how and why malignant lymphocytes develop resistance to currently prescribed drugs, including those that inhibit B-cell receptor and Bcl-2 pathways. Understanding these mechanisms is critical for the development of novel therapies to effectively treat the many types of lymphoid malignancies, which the center also seeks to do. Further, the Lymphocenter team will develop a variety of cellular and preclinical models for exploration of novel single agent and rational combination therapies.

Shared resources and services, including biorepositories of blood and tumor tissue samples and a lentiviral core, will be created and are expected to expedite scientific discovery and drug development.

Neetu Gupta, PhD, Department of Inflammation & Immunity, Lerner Research Institute, and Brian Hill, MD, PhD, Department of Hematology and Medical Oncology, Cleveland Clinic Cancer Center, are leading the new COE.

“The Lymphocenter is actively engaged in understanding the basis of resistance and relapse in B cell lymphoma and developing novel small molecule and cellular immunotherapies for treatment of lymphoma patients,” says Dr. Gupta. “We utilize primary patient specimens to investigate causes of treatment success/failure in order to translate our finding to improve and customize patient care.”

Dr. Gupta’s lab investigates molecular mechanisms of B cell activation that regulate humoral immunity and pathogenesis of B cell-mediated diseases. Dr. Hill directs Cleveland Clinic Cancer Center’s Lymphoid Malignancies Program and is principal investigator of several ongoing clinical trials.

Feature image: Transmission electron micrograph of a B cell from a human donor. Credit: National Institutes of Allergy and Infectious Diseases, National Institutes of Health.


Related Articles

23-CCC-3771004 Quantum computer 650×450
Quantum Computing Debuts at Cleveland Clinic

Discovery Accelerator Partnership with IBM Deploys Advanced Computing Technologies to Supercharge Healthcare Research

Idyllic neighborhood street, aerial view
Digital Twin Neighborhoods: An Advanced Tool to Tackle Health Disparities

Testable models of communities can identify effective strategies to address place-based inequalities of care

22-CCC-3308323 Quantum computing 650×450
How We’re Bringing the Power of Quantum Computing to Medical Research

Cleveland Clinic is a Founding Partner in Quantum Innovation Hub

When Two Fields Collide: One Biomedical Engineer’s Passion to Innovate Surgical Care

Leveraging Microsoft HoloLens and 3D printing to improve surgical outcomes

Decades of Research Bring New Understanding of ILK

The pseudokinase binds to proteins to form IPP

15-URL-2411 Urinary Incontinence
Bladder Sensor for Diagnosis and Treatment of Urinary Incontinence

A ‘fitness tracker for the bladder’ as replacement for urodynamic testing?